Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)

Inclusion Criteria:

- Cytologically or histologically confirmed advanced solid tumor

- Radiographic progression on prior systemic therapy; prior localized therapy (i.e.,
radiation, ablation, embolization) is allowed provided radiographic progression
out-of-field or in the treatment, field is shown

- Locally-advanced (unresectable) or metastatic disease harboring an FGFR1-3 gene
fusion/rearrangement potentially leading to a functional FGFR aberrant protein,
identified through local and/or central molecular assay

Exclusion Criteria:

- History of hypersensitivity to any of the excipients in the Debio 1347 formulation

- History and/or current evidence of ectopic mineralization/calcification, including but
not limited to soft tissue, kidneys, intestine, myocardia, or lung, excepting
calcified lymph nodes, lung nodules and asymptomatic vascular or cartilage/tendon
calcifications

- Administration of any investigational agent within 2 weeks prior to initial dosing
with Debio 1347 (3 weeks for immune checkpoint inhibitors)